[Federal Register Volume 61, Number 47 (Friday, March 8, 1996)]
[Notices]
[Page 9464]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-5509]



-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Heart, Lung, and Blood Institute; Notice of Meeting

    Pursuant to Pub. L. 92-463, notice is hereby given of the meeting 
of the following Heart, Lung, and Blood Special Emphasis Panel.
    This meeting will be open to the public to provide concept review 
of proposed contract or grant solicitations.
    Individuals who plan to attend and need special assistance, such as 
signed language interpretation or other reasonable accommodations, 
should inform the Contact Person listed below in advance of the 
meeting.

    Name of Panel: Pediatric Hydroxyurea Phase III Clinical Trial.
    Dates of Meeting: April 12, 1996.
    Time of Meeting: 10:00 a.m.
    Place of Meeting: National Institutes of Health, Two Rockledge 
Center, Room 9A2, 6701 Rockledge Drive, Bethesda, Maryland 20892.
    Agenda: To review Phase III Pediatric Hydroxyurea in Sickle Cell 
Anemia Trial.
    Contact Person: Duane R. Bonds, M.D., Rockledge II Building, Rm. 
10158, 6701 Rockledge Drive, Bethesda, Maryland 20892-7950, (301) 
435-0055.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart 
and Vascular Diseases Research; 93.838, Lung Diseases Research; and 
93.839, Blood Diseases and Resources Research, National Institutes 
of Health)

    Dated: March 5, 1996.
Susan K. Feldman,
Committee Management Officer, NIH.
[FR Doc. 96-5509 Filed 3-7-96; 8:45 am]
BILLING CODE 4140-01-M